Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.57 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.57 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.57 |
| ▸ | CTRC | Q99895 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CTSV | O60911 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894291 | 0.93 | GPR132 (0.60) | ECE1RAB9AGAAALDH1A1LMNA | |
| SCHEMBL2229647 | 0.90 | LNPEP (0.60) | ECE1RAB9AGAAGPR132CMKLR2 | |
| SCHEMBL23489730 | 0.87 | ECE1 (0.65) | ECE1RAB9AALDH1A1LMNAGPR132 | |
| SCHEMBL30037998 | 0.87 | GPR132 (0.69) | ECE1RAB9ALMNAGPR132CMKLR2 | |
| SCHEMBL3497405 | 0.87 | GPR132 (0.69) | ECE1RAB9ALMNAGPR132CMKLR2 | |
| SCHEMBL2229201 | 0.87 | GPR132 (0.69) | ECE1RAB9ALMNAGPR132CMKLR2 | |
| SCHEMBL31206887 | 0.87 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL2461492 | 0.87 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL1793176 | 0.87 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL6093237 | 0.86 | GAA (0.64) | RAB9AGAAALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| CN-102712595-B | Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTTICS SA | 2015-04-22 | — | — | CN | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| CN-102712595-A | Novel compositions for reducing A beta 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTTICS SA | 2012-10-03 | — | — | CN | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | ECE1 3655/4885RAB9A 1610/4885GAA 70/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | ECE1 3655/4885RAB9A 1610/4885GAA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.